HOME >> BIOLOGY >> NEWS
Phase II trials of second-generation antisense cancer drug planned following successful early study

Geneva, Switzerland: Phase II trials of the first second-generation antisense cancer drug to be used in patients are soon to be underway in the wake of a successful Phase I study, which has demonstrated that the new drug blocks its target gene in exactly the way it is designed to do.

In the Phase I study the drug OGX-011* inhibited the production of clusterin, a protein that protects cell survival and is widely distributed in body tissue. Clusterin is implicated in a range of activities, including apoptosis (programmed cell death). When it is over-produced, as it is many major cancers, clusterin can stop cancer cells from dying and counters the effectiveness of chemotherapy, hormone treatment and radiotherapy.

Dr. Kim Chi, assistant professor of medicine at the University of British Columbia and medical oncologist at the BC Cancer Agency in Canada, told the EORTC-NCI-AACR[1] Symposium on Molecular Targets and Cancer Therapeutics in Geneva today (Wednesday 29 September) that the Phase I trial was unique in that the clinical research team was able to demonstrate that the target clusterin was inhibited by OGX-011 in patients' cancers in a dose dependent way.

"This means that the drug is doing what it is supposed to be doing something that we can't always say about targeted therapeutics and we were able to identify a biologically active dose," he said.

Antisense drugs work by inhibiting the production of a protein from a specifically targeted gene. As a second-generation antisense drug, OGX-011 is an advance on earlier ones in that the molecules have a longer tissue half life and are potentially more potent. Pre-clinical studies had shown that blocking the production of clusterin with OGX-011 impairs a cancer cell's survival mechanism and enhances the effectiveness of standard chemotherapy, radiation and hormone therapy.

Twenty-five patients with localised prostate cancer that was to be removed by surgery were given escalati
'"/>

Contact: Margaret Willson
m.willson@mwcommunications.org.uk
41-227-612-205
European Organisation for Research and Treatment of Cancer
29-Sep-2004


Page: 1 2

Related biology news :

1. OneWorld Health completes enrollment, treatment in Phase III India trial
2. Landmark, pivotal Phase IIb/III trial of biotoxin for cancer pain begins
3. VaxGen reports Phase I clinical trial results of anthrax vaccine candidate
4. Critical Therapeutics launches Phase I clinical trial of anti-inflammatory compound
5. KEPPRA international Phase IV SKATE study results show favourable efficacy
6. Phase III study results with Raptiva in the treatment of psoriasis presented at Annual AAD meeting
7. Phase III, 48-Wk NEAT study results comparing GW433908 to Nelfinavir presented today
8. OXiGENE announces commencement of Phase I/II clinical trial of Combretastatin A4 Prodrug
9. Acorda therapeutics receives NIH Phase 2 grant for central nervous system repair
10. Phase transition in bilayers could affect their performance
11. Acorda Therapeutics begins Phase 3 trials of Fampridine-SR for chronic spinal cord injury

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/31/2020)... ... July 30, 2020 , ... BioFactura, Inc. ... awarded by the Joint Science & Technology Office—Chemical and Biological Defense (JSTO-CBD) of ... optimize, and scale-up a highly efficient mammalian cell culture-based bioprocess suitable to meet ...
(Date:7/18/2020)... TORONTO (PRWEB) , ... July 17, 2020 , ... Commercial ... hangs on pharma’s ability to discover a COVID cure or vaccine, the global economic ... competitive and price pressure is not going away and capturing full value from every ...
(Date:7/2/2020)... (PRWEB) , ... July 01, 2020 , ... ... presented its phase 1a findings of Neihulizumab, a biologic for the treatment of ... June 2020. Led by hemato-oncologist Dr. Paul J Martin of the Fred Hutchinson ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... ... 12, 2020 , ... Inc. magazine today revealed that ... compliance consulting has been named on its annual Inc. 5000 list, the most ... look at the most successful companies within the American economy’s most dynamic segment—its ...
(Date:7/31/2020)... ... July 29, 2020 , ... G-CON ... of its new tagline, “BUILDING FOR LIFE.” The adoption of this taglines comes ... globe, requiring fast track capacity to provide patients with urgently needed vaccines and ...
(Date:7/31/2020)... ... July 29, 2020 , ... The ... centers in 16 countries, has reached its 20th anniversary of worldwide use. Introduced ... use at top universities including University of Pennsylvania, University of Michigan, University of ...
(Date:7/18/2020)... ... July 16, 2020 , ... Medial EarlySign , a ... prevention of high-burden diseases, and Centric Consulting, a business and technology consulting firm, ... existing data in order to identify and prioritize patients for care. , Combining ...
Breaking Biology Technology:
Cached News: